Latest Breaking News On - Hifa launches with seed financing to address cardiovascular disease by developing orally bioavailable drugs for the treatment of dyslipidemia - Page 1 : comparemela.com
Published: May 12, 2021
MALVERN, Pa. (BUSINESS WIRE) Shifa Biomedical Corporation (Shifa), a drug discovery company developing an oral small molecule PCSK9/low density lipoprotein-cholesterol receptor (LDLR) antagonist, P-21, to treat dyslipidemia, today announced their launch with a seed investment from Xontogeny, LLC to advance their lead program through IND-enabling research.
“We are excited to announce our collaboration with Shifa to address the unmet need for oral drugs that can treat dyslipidemia without the need for injections,” said Chris Garabedian, Founder, Chairman and Chief Executive Officer of Xontogeny. “The expertise of our team at Xontogeny complements that of the team at Shifa, and we are aligned on the key milestones we plan to achieve with this seed investment.”